Comparative Pharmacology
Head-to-head clinical analysis: SIGNIFOR versus SIGNIFOR LAR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIGNIFOR versus SIGNIFOR LAR KIT.
SIGNIFOR vs SIGNIFOR LAR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Somatostatin analog; inhibits growth hormone (GH), insulin-like growth factor 1 (IGF-1), and other hormones.
Somatostatin analog that binds to somatostatin receptors (primarily sst2 and sst5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, and reducing hormone release from neuroendocrine tumors.
Subcutaneous injection: 0.3 mg twice daily; Intravenous bolus: 0.9 mg (for Cushing's disease perioperatively).
Intramuscular injection: 40 mg every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours in healthy subjects. In patients with renal impairment, half-life may be prolonged (up to 10 hours in severe impairment).
Terminal elimination half-life following intramuscular injection of the long-acting formulation is approximately 19 days (range 15–23 days), supporting monthly dosing intervals.
Primarily renal (approximately 80% of the dose excreted unchanged in urine), with about 20% eliminated via biliary/fecal routes. Renal clearance accounts for ~70% of total clearance.
Primarily renal (approximately 85% of administered dose excreted unchanged in urine); minimal biliary/fecal excretion (less than 10%).
Category C
Category C
Somatostatin Analog
Somatostatin Analog